EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma

Chenkai Mao iD, Maria Poimenidou iD, Brian T Craig iD

Cancers · 17.08.2024 · 16 (16) · 2865

DOI: 10.3390/cancers16162865 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.08.2024. Verfasst von Chenkai Mao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Center for Advancing Translational Sciences, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroblastoma (NBL) cells highly express disialoganglioside GD2, which is restricted and weakly expressed in selected healthy cells, making it a desirable target of immunotherapy. Over the past two decades, application of dinutuximab, an anti-GD2 monoclonal antibody (mAb), has been one of the few new therapies to substantially improve outcomes to current levels. Given the persistent challenge of relapse and therapeutic resistance, there is an urgent need for new effective and tolerable treatment options for high-risk NBL. Recent breakthroughs in immune checkpoint inhibitor (ICI) therapeutics have not translated into high-risk NBL, like many other major pediatric solid tumors. Given the suppressed tumor microenvironment (TME), single ICIs like anti-CTLA4 and anti-PD1 have not demonstrated significant antitumor response rates. Meanwhile, emerging studies are reporting novel advancements in GD2-based therapies, targeted therapies, nanomedicines, and other immunotherapies such as adoptive transfer of natural killer (NK) cells and chimeric antigen receptors (CARs), and these hold interesting promise for the future of high-risk NBL patient care. Herein, we summarize the current state of the art in NBL therapeutic options and highlight the unique challenges posed by NBL that have limited the successful adoption of immune-modifying therapies. Through this review, we aim to direct the field’s attention to opportunities that may benefit from a combination immunotherapy strategy.

Schlagwörter

Stichwörter der Autor:innen

immunosuppressionimmunotherapyneuroblastomatumor microenvironment

Autor:innen und Institutionen

  • Department of Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
  • Center for Immunology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

ORCID-Profile: Chenkai Mao, Maria Poimenidou, Brian T Craig

Förderung

  • NIH HHS
  • National Center for Advancing Translational Sciences, National Institutes of Health

Zitieren

APA

Mao, C., Poimenidou, M., & Craig, B. T. (2024). Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma. Cancers, 16(16), 2865. https://doi.org/10.3390/cancers16162865

Vancouver

Mao C, Poimenidou M, Craig BT. Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma. Cancers. 2024;16(16):2865. doi:10.3390/cancers16162865

BibTeX
@article{Mao2024,
  author = {Mao, Chenkai and Poimenidou, Maria and Craig, Brian T},
  title = {Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {16},
  pages = {2865},
  doi = {10.3390/cancers16162865}
}
Kostenlos starten →